NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Nov 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Melanocortin 4 Receptor Agonists
Pharmacologic Class:
Melanocortin 4 Receptor Agonist
Clinical Trials (5)
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Started Sep 2025
39 enrolled
Hypothalamic ObesityMultiple Pituitary Hormone Deficiency Genetic FormSepto-Optic Dysplasia+3 more
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Started Mar 2025
18 enrolled
Prader-Willi SyndromeObesityHyperphagia
Open-Label Extension Study of Setmelanotide
Started Oct 2024
30 enrolled
Obesity Associated With Defects in Leptin-melanocortin Pathway
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Started Apr 2023
120 enrolled
Hypothalamic Obesity
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity
Started Mar 2022
12 enrolled
Bardet-Biedl SyndromePOMC Deficiency ObesityPCSK1 Deficiency Obesity+1 more
Loss of Exclusivity
LOE Date
Jul 4, 2034
101 months away
Patent Expiry
Jul 4, 2034
Exclusivity Expiry
Dec 20, 2031